Prosecution Insights
Last updated: May 29, 2026

Sutro Biopharma, Inc.

8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
5
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (12%)
2
Easy (25%)
5
Unknown (62%)

Rejection Statute Mix

BucketCases
§103 only1 (12%)
§112 only2 (25%)
No statute on record5 (62%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KAUFMAN, CLAIRE M 1 62.8% +51.3%
REGLAS, GEORGIANA C 1 38.8% +30.2%
LU, CHENG 1 54.1% +67.9%
HELLMAN, KRISTINA M 1 66.0% +54.3%
HUYNH, PHUONG N 1 65.7% +53.3%
ESSEX, LAURA ANN 1 59.6% +33.8%
RYAN, DOUGLAS CHARLES 1 40.0% +48.9%
PERSONS, JENNA L 1 52.8% +65.0%

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17276757 COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES ESSEX, LAURA ANN 46d overdue
18203348 IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF HELLMAN, KRISTINA M 26d overdue
16991607 EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION RYAN, DOUGLAS CHARLES 18d overdue
18357966 ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME LU, CHENG 2d overdue
17727395 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N 2d overdue
16395649 HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE PERSONS, JENNA L 6d
18638420 ANTI-BCMA ANTIBODIES AND TREATMENT METHODS KAUFMAN, CLAIRE M 15d
18231204 SPRAY DRIED EXTRACT REGLAS, GEORGIANA C 22d

Top Art Units

Art UnitApps
1674 1
1651 1
1642 1
1654 1
1641 1
1675 1
1635 1
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18638420 ANTI-BCMA ANTIBODIES AND TREATMENT METHODS KAUFMAN, CLAIRE M 1674 Other Final Rejection 15d Pending Apr 17, 2024
18231204 SPRAY DRIED EXTRACT REGLAS, GEORGIANA C 1651 §103 Non-Final OA 22d Pending Aug 07, 2023
18357966 ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME LU, CHENG 1642 Other Final Rejection 2d overdue Pending Jul 24, 2023
18203348 IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF HELLMAN, KRISTINA M 1654 §112 Final Rejection 26d overdue Pending May 30, 2023
17727395 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N 1641 Other Non-Final OA 2d overdue Pending Apr 22, 2022
17276757 COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES ESSEX, LAURA ANN 1675 §112 Non-Final OA 46d overdue Pending Mar 16, 2021
16991607 EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION RYAN, DOUGLAS CHARLES 1635 Other Non-Final OA 18d overdue Pending Aug 12, 2020
16395649 HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE PERSONS, JENNA L 1637 Other Non-Final OA 6d Pending Apr 26, 2019

Managing Sutro Biopharma, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month